This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, H. K.
Right arrow Articles by Nicolau, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, H. K.
Right arrow Articles by Nicolau, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 788-790, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.788-790.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects

Heather K. Sun,1 Kenneth Duchin,2 Charles H. Nightingale,1 Jeng-Pyng Shaw,2 Julie Seroogy,2 and David P. Nicolau1,3*

Center for Anti-Infective Research and Development,1 Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut 06102,3 Theravance, Inc., South San Francisco, California 940802

Received 1 August 2005/ Returned for modification 20 August 2005/ Accepted 24 November 2005

The pharmacokinetic disposition of telavancin administered 7.5 mg/kg of body weight every 24 h was determined in plasma and skin blister fluid. The mean penetration of telavancin into blister fluid was 40%. This study reveals that adequate concentrations are achieved in both plasma and blister fluid for pathogens frequently implicated in skin and soft tissue infections.

* Corresponding author. Mailing address: Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102. Phone: (860) 545-3941. Fax: (860) 545-3992. E-mail: dnicola{at}harthosp.org.

Antimicrobial Agents and Chemotherapy, February 2006, p. 788-790, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.788-790.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wong, S. L., Sorgel, F., Kinzig, M., Goldberg, M. R., Kitt, M. M., Barriere, S. L. (2009). Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy Participants. J Clin Pharmacol 49: 816-823 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Gotfried, M., Barriere, S., Drusano, G. L. (2008). Telavancin Penetration into Human Epithelial Lining Fluid Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation. Antimicrob. Agents Chemother. 52: 2300-2304 [Abstract] [Full Text]  
  • Barcia-Macay, M., Mouaden, F., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F. (2008). Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 61: 1288-1294 [Abstract] [Full Text]  
  • Gotfried, M. H., Shaw, J.-P., Benton, B. M., Krause, K. M., Goldberg, M. R., Kitt, M. M., Barriere, S. L. (2008). Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics. Antimicrob. Agents Chemother. 52: 92-97 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Nicolau, D. P., Sun, H. K., Seltzer, E., Buckwalter, M., Dowell, J. A. (2007). Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 60: 681-684 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»